Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ETHAMBUTOL HCL

All products: general benefit

Other products in the same Health Canada class (J04A) — coverage varies; not interchangeable

  • Rifampin (Rofact): general benefit
  • Rifabutin (Mycobutin): limited Use 103, 104, Listing status unconfirmed

Etibi · DIN 00247979 · 400mg · tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Etibi · DIN 00247979 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2019-07-10 · brand ETIBI · ATC J04AK02 ETHAMBUTOL · form Tablet · route Oral · ingredients ETHAMBUTOL HYDROCHLORIDE 400 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Etibi: Formulary list price $0.8522/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1472 · Verify on the e-Formulary ↗ (DIN 00247979)

Source record
DIN 00247979: Etibi Raw flags: sec3=Y Item: 081600003; group id 55; item number 0113; lccId None; manufacturer id VAL Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.8522; ministry $0.8522 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00247979 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1472
Interchangeable products
Myambutol · DIN 02170078 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:16 Antitubercular Agents) and how they are covered

Matched class: 08:16 Antitubercular Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: RIFAMPIN 08:16 Antitubercular Agents

RIFAMPIN

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

RIFABUTIN

· 2 products · Limited Use, codes 103, 104 (1), Temporary benefit (1) · strengths: 150mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:16
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications ETIBI (ethambutol) is indicated in combination with other antituberculosis medications for: • Treatment of all forms of tuberculosis, including tuberculous meningitis, caused by Mycobacterium tuberculosis. In retreatment cases, Etibi should be given together with at least one other second line drug for which bacterial susceptibility has been indicated by appropriate in vitro studies and which has not been administered previously to the patient. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Etibi Tablets and other antibacterial drugs, Etibi Tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 1.1. Pediatrics Pediatrics (˂ 13 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics It is unknown if … https://pdf.hres.ca/dpd_pm/00082029.PDF PM date: not printed or not captured Source product: ETIBI; DIN 00247960; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.